EC 1.14.13.39 (nitric oxide synthase) inhibitor

Term ID

CHEBI:61908

Synonyms

EC 1.14.13.39 (nitric oxide synthase) inhibitors
EC 1.14.13.39 inhibitor
EC 1.14.13.39 inhibitors
endothelium-derived relaxation factor-forming enzyme inhibitor
endothelium-derived relaxation factor-forming enzyme inhibitors
endothelium-derived relaxing factor synthase inhibitor
endothelium-derived relaxing factor synthase inhibitors
NADPH-diaphorase inhibitor
NADPH-diaphorase inhibitors
nitric oxide synthase (EC 1.14.13.39) inhibitor
nitric oxide synthase (EC 1.14.13.39) inhibitors
nitric oxide synthase inhibitor
nitric oxide synthase inhibitors
nitric oxide synthetase inhibitor
nitric oxide synthetase inhibitors
nitric-oxide synthetase inhibitor
nitric-oxide synthetase inhibitors
NO synthase inhibitor
NO synthase inhibitors

Definition

An EC 1.14.13.* (oxidoreductase acting on paired donors, incorporating 1 atom of oxygen, with NADH or NADPH as one donor) inhibitor that interferes with the action of nitric oxide synthase (EC 1.14.13.39).

References

Wikipedia:Nitric_oxide_synthase

Ontology

ChEBI ( EBI )

Relationships

is a type of: EC 1.14.13.* (oxidoreductase acting on paired donors, incorporating 1 atom of oxygen, with NADH or NADPH as one donor) inhibitor

EC 1.14.13.* (oxidoreductase acting on paired donors, incorporating 1 atom of oxygen, with NADH or NADPH as one donor) inhibitor Show first 5 Terms
inverse has_role: (-)-demethoxylpinoresinol (2R*,3R*)-2,3-dihydro-7-hydroxy-2,3-dimethyl-2-[4,8-dimethyl-3(E)-7-nonadien-6-onyl]furo[3,2-c]coumarin (2S*,3R*)-2,3-dihydro-7-hydroxy-2,3-dimethyl-2-[4,8-dimethyl-3(E),7-nonadien-6-onyl]-furo[3,2-c]coumarin (2S*,3R*)-2,3-dihydro-7-methoxy-2,3-dimethyl-2-[4-methyl-5-(4-methyl-2-furyl)-3(E)-pentenyl]-furo[3,2-c]coumarin (RS)-mallotophilippen E ... Show All 64 Terms

(-)-demethoxylpinoresinol (2R*,3R*)-2,3-dihydro-7-hydroxy-2,3-dimethyl-2-[4,8-dimethyl-3(E)-7-nonadien-6-onyl]furo[3,2-c]coumarin (2S*,3R*)-2,3-dihydro-7-hydroxy-2,3-dimethyl-2-[4,8-dimethyl-3(E),7-nonadien-6-onyl]-furo[3,2-c]coumarin (2S*,3R*)-2,3-dihydro-7-methoxy-2,3-dimethyl-2-[4-methyl-5-(4-methyl-2-furyl)-3(E)-pentenyl]-furo[3,2-c]coumarin (RS)-mallotophilippen E 1-(4'-hydroxy-3'-methoxyphenyl)-7-phenyl-3-heptanone 1-O-acetyl-4R,6S-britannilactone 3-O-methyl-isosecotanapartholide 4-hydroxycinnamaldehyde 5-hydroxyzerumbone 6-propyl-2-thiouracil ainsliadimer A aminoguanidine bis(7)-tacrine dihydroxanthohumol formamidine fukanefuromarin A fukanefuromarin B fukanefuromarin C fukanefuromarin D fukanefuromarin E fukanefuromarin F fukanefuromarin G fukanemarin A fukanemarin B futokadsurin A futokadsurin B futokadsurin C indicanone isosecotanapartholide L-citrulline L-glutamine mallotophilippen A mallotophilippen B mallotophilippen C mallotophilippen D methyl propenyl ketone methylguanidine myricitrin N(6)-acetimidoyl-L-lysine dihydrochloride N(gamma)-nitro-L-arginine methyl ester N(gamma)-nitro-L-arginine methyl ester hydrochloride N(omega),N'(omega)-dimethyl-L-arginine N(omega),N(omega)-dimethyl-L-arginine N-[3-(aminomethyl)benzyl]acetamidine nitroflurbiprofen oroxylin A oroxylin A(1-) oxygenated xanthohumol paraminabeolide A paraminabeolide B paraminabeolide C paraminabeolide D phoyunbene A phoyunbene B phoyunbene C phoyunbene D S-methyl-L-thiocitrulline thienodolin triptoquinone A xanthohumol B xanthohumol D zaluzanin C zerumboneoxide Show first 5 Terms

Phenotype

Phenotype resulting from EC 1.14.13.39 (nitric oxide synthase) inhibitor

Phenotype where environments contain EC 1.14.13.39 (nitric oxide synthase) inhibitor

Phenotype modified by environments containing EC 1.14.13.39 (nitric oxide synthase) inhibitor

Human Disease Model